▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3586 by analyst upside · 2026-06-27
QTRX
Quanterix Corporation
Healthcare · Market Cap $203M · P/E 0x
ANALYST PRICE TARGET
+0.3%
implied upside to consensus target
Current Price $4.32
Consensus Target $4.33
Bull Target $5.0
Bear Target $4.0
Analysts Covering 3
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
0
Hold
3
Sell
0
52-Week Low $2.4
52-Week High $8.77
YTD Return -32.8%
FUNDAMENTALS
Market Cap $203M
P/E Ratio (TTM) N/A
Forward P/E -3.2x
EPS (TTM) $-2.35
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $145M
Profit Margin -71.9%
52-WEEK RANGE
52-Week Low $2.4
52-Week High $8.77
Current Price $4.32
Bear Target $4.0
Bull Target $5.0
● Now $4.32 ● Target $4.33
TRADING DATA
Avg Volume 1.2M
YTD Return -32.8%
Analyst Count 3
Consensus Hold
Upside to Target +0.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Quanterix Corporation (QTRX) is currently trading at $4.32 with a Wall Street consensus price target of $4.33, implying potential upside of 0.3% over the next 12 months. 3 analysts currently cover QTRX, with a consensus rating of Hold - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $5.0, while the most cautious has a target of $4.0.

QTRX operates in the Healthcare sector with a market capitalisation of $203M. The stock is down 32.8% year-to-date and is currently trading near the lower end of its 52-week range of $2.4 – $8.77.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

QTTB +8.2%
Q32 Bio Inc.
$223M · P/E 4.7x · Buy
EMBC +14.6%
Embecta Corp.
$207M · P/E 1.8x · Underperform
PDEX +13.9%
Pro-Dex, Inc.
$196M · P/E 18.2x · Buy
ORMP +33.8%
Oramed Pharmaceuticals Inc.
$191M · P/E 1.8x · Hold
SPOK +31.5%
Spok Holdings, Inc.
$222M · P/E 18.1x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for QTRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

TD Cowen — Reiterated
Hold → Hold 2026-05-07 Building track record
Canaccord Genuity — Reiterated
Hold → Hold 2026-04-20 Building track record
Canaccord Genuity — Reiterated
Hold → Hold 2025-12-22 Building track record
Canaccord Genuity ↓ Downgrade
Buy → Hold 2025-08-11 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2025-05-13 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2025-04-30 29% win rate (7 calls)
Scotiabank — Reiterated
Sector Outperform → Sector Outperform 2025-03-25 20% win rate (5 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-03-18 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
11/30
Consensus clarity
25/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →